Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Favipiravir  COVID-19 treatment studies for Favipiravir  C19 studies: Favipiravir  Favipiravir   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent: 
0 0.5 1 1.5 2+ Mortality -263% Improvement Relative Risk Oxygen therapy 41% Hospitalization time -40% c19favipiravir.com Al-Muhsen et al. Favipiravir for COVID-19 LATE Favors favipiravir Favors control
Al-Muhsen, 598 patient favipiravir late treatment study: 263% higher mortality [p=0.04], 41% lower need for oxygen therapy [p<0.0001], and 40% longer hospitalization [p=0.03] https://c19p.org/almuhsen
copied to clipboard
Favipiravir Effectiveness and Safety in Hospitalized Moderate-Severe COVID-19 Patients: Observational Prospective Multicenter Investigation in Saudi Arabia
Al-Muhsen et al., Frontiers in Medicine, doi:10.3389/fmed.2022.826247
4 Mar 2022    Source   PDF   Share   Tweet
Prospective observational study of 598 hospitalized patients in Saudi Arabia, showing higher risk of mortality and longer hospitalization time with favipiravir.
risk of death, 263.0% higher, HR 3.63, p = 0.04, treatment 156, control 442, Cox proportional hazards.
risk of oxygen therapy, 40.6% lower, RR 0.59, p < 0.001, treatment 52 of 156 (33.3%), control 248 of 442 (56.1%), NNT 4.4.
hospitalization time, 40.0% higher, relative time 1.40, p = 0.03, treatment 156, control 442.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Al-Muhsen et al., 4 Mar 2022, prospective, Saudi Arabia, peer-reviewed, 11 authors, study period June 2020 - January 2021.
Contact: almuhsen@ksu.edu.sa, rhalwani@sharjah.ac.ae, hayakbaa@gmail.com.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperFavipiravirAll
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit